NEWTON, Mass., Dec. 1, 2020 /PRNewswire/ -- Karyopharm
Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical
company pioneering novel cancer therapies, today announced that it
will host a virtual investor and analyst event to discuss the
Company's pipeline of clinical programs and highlights from the
data presentations being given at the American Society of
Hematology (ASH) 2020 Annual Meeting. This Karyopharm-sponsored
event is scheduled for Tuesday, December 8,
2020 from 1:00 - 2:30 p.m.
ET.
The Karyopharm management team will be joined by a group of
recognized multiple myeloma, diffuse large B-cell Lymphoma and
leukemia experts to provide additional external context and
participate in the Q&A portion of the call.
To access the event, please dial (877) 870-4263 (local) or (412)
317-0790 (international) at least 10 minutes prior to the start
time and ask to be joined into the Karyopharm Therapeutics call.
A live audio webcast of the call will be available under
"Events & Presentations" in the Investor section of the
Company's website,
http://investors.karyopharm.com/events-presentations. An archived
webcast will be available on the Company's website approximately
two hours after the event.
About Karyopharm Therapeutics
Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is a
commercial-stage pharmaceutical company pioneering novel cancer
therapies and dedicated to the discovery, development, and
commercialization of novel first-in-class drugs directed against
nuclear export and related targets for the treatment of cancer and
other major diseases. Karyopharm's Selective Inhibitor of Nuclear
Export (SINE) compounds function by binding with and inhibiting the
nuclear export protein XPO1 (or CRM1). Karyopharm's lead compound,
XPOVIO® (selinexor), received accelerated approval from the U.S.
Food and Drug Administration (FDA) in July
2019 in combination with dexamethasone as a treatment for
patients with heavily pretreated multiple myeloma. In June 2020, XPOVIO was approved by the FDA as a
treatment for patients with relapsed or refractory diffuse large
B-cell lymphoma. A Marketing Authorization Application for
selinexor for patients with heavily pretreated multiple myeloma is
also currently under review by the European Medicines Agency. In
addition to single-agent and combination activity against a variety
of human cancers, SINE compounds have also shown biological
activity in models of neurodegeneration, inflammation, autoimmune
disease, certain viruses and wound-healing. Karyopharm has several
investigational programs in clinical or preclinical development.
For more information, please visit www.karyopharm.com.
View original
content:http://www.prnewswire.com/news-releases/karyopharm-announces-investor-and-analyst-event-at-the-american-society-of-hematology-2020-annual-meeting-301183034.html
SOURCE Karyopharm Therapeutics Inc.